PANOBINOSTAT: 1,820 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,820
Total FAERS Reports
517 (28.4%)
Deaths Reported
623
Hospitalizations
1,820
As Primary/Secondary Suspect
119
Life-Threatening
17
Disabilities
Feb 23, 2015
FDA Approved
Discontinued
Status
FDA Application: 205353 ·
Patent Expires: Jun 13, 2028 · First Report: 16000223 · Latest Report: 20240612
What Are the Most Common PANOBINOSTAT Side Effects?
#1 Most Reported
Diarrhoea
368 reports (20.2%)
#2 Most Reported
Plasma cell myeloma
279 reports (15.3%)
#3 Most Reported
Platelet count decreased
192 reports (10.5%)
All PANOBINOSTAT Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 368 | 20.2% | 76 | 124 |
| Plasma cell myeloma | 279 | 15.3% | 170 | 80 |
| Platelet count decreased | 192 | 10.6% | 72 | 90 |
| Death | 190 | 10.4% | 189 | 17 |
| Malignant neoplasm progression | 166 | 9.1% | 104 | 61 |
| Fatigue | 162 | 8.9% | 28 | 46 |
| Nausea | 154 | 8.5% | 44 | 63 |
| Thrombocytopenia | 141 | 7.8% | 30 | 60 |
| Off label use | 112 | 6.2% | 37 | 9 |
| Vomiting | 109 | 6.0% | 20 | 60 |
| Drug ineffective | 105 | 5.8% | 46 | 18 |
| Pneumonia | 99 | 5.4% | 39 | 69 |
| Pyrexia | 98 | 5.4% | 40 | 65 |
| Anaemia | 95 | 5.2% | 39 | 49 |
| White blood cell count decreased | 83 | 4.6% | 35 | 49 |
| Disease progression | 71 | 3.9% | 26 | 3 |
| Febrile neutropenia | 61 | 3.4% | 11 | 32 |
| Malaise | 61 | 3.4% | 20 | 31 |
| Neutrophil count decreased | 53 | 2.9% | 18 | 31 |
| Constipation | 51 | 2.8% | 17 | 19 |
Who Reports PANOBINOSTAT Side Effects? Age & Gender Data
Gender: 49.7% female, 50.3% male. Average age: 61.8 years. Most reports from: US. View detailed demographics →
Is PANOBINOSTAT Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2008 | 1 | 0 | 1 |
| 2009 | 7 | 1 | 5 |
| 2010 | 6 | 0 | 5 |
| 2011 | 29 | 1 | 27 |
| 2012 | 14 | 1 | 12 |
| 2013 | 12 | 1 | 11 |
| 2014 | 38 | 6 | 34 |
| 2015 | 282 | 86 | 114 |
| 2016 | 231 | 100 | 106 |
| 2017 | 115 | 44 | 69 |
| 2018 | 96 | 22 | 57 |
| 2019 | 60 | 20 | 34 |
| 2020 | 64 | 20 | 30 |
| 2021 | 15 | 6 | 5 |
| 2022 | 5 | 1 | 1 |
| 2023 | 4 | 4 | 4 |
| 2024 | 1 | 0 | 1 |
What Is PANOBINOSTAT Used For?
| Indication | Reports |
|---|---|
| Plasma cell myeloma | 1,262 |
| Product used for unknown indication | 244 |
| Plasma cell myeloma refractory | 49 |
| Acute myeloid leukaemia | 33 |
| Brain stem glioma | 15 |
| Plasmacytoma | 14 |
| Hodgkin's disease | 13 |
| Plasma cell leukaemia | 12 |
| Glioma | 10 |
| Graft versus host disease | 10 |
PANOBINOSTAT vs Alternatives: Which Is Safer?
PANOBINOSTAT vs PANTOPRAZOLE
PANOBINOSTAT vs PANTOPRAZOLE ANHYDROUS
PANOBINOSTAT vs PANTOTHENIC ACID
PANOBINOSTAT vs PAPAVERINE
PANOBINOSTAT vs PARACETAMOL
PANOBINOSTAT vs PARATHYROID HORMONE
PANOBINOSTAT vs PARECOXIB
PANOBINOSTAT vs PARICALCITOL
PANOBINOSTAT vs PARITAPREVIR
PANOBINOSTAT vs PAROXETINE
Official FDA Label for PANOBINOSTAT
Official prescribing information from the FDA-approved drug label.